

Morgan Stanley makes historic entry into Indian healthcare with ClearMedi majority stake for Rs 285 Cr

04 September 2023 | News

Morgan Stanley's Private Equity (PE) arm has purchased a majority stake in ClearMedi Healthcare



In a historic move marking Morgan Stanley's debut in the Indian healthcare landscape, the global financial powerhouse has acquired a majority stake in Gurugram-based ClearMedi Healthcare. Under the leadership of Commander Navneet Bali, Morgan Stanley-backed ClearMedi Healthcare is all set to chart an ambitious path toward solidifying its position in the industry.

Commander Bali, with an illustrious 25-year career in the Indian Navy and successful leadership roles at Narayana Health and IOSPL, is well-poised to lead ClearMedi Healthcare to new heights of success.

Morgan Stanley's backing adds substantial momentum to ClearMedi's market presence. With Morgan Stanley's vast financial expertise and resources, ClearMedi is strategically positioned to expand its reach, invest in cutting-edge technologies, and uphold its commitment to delivering exceptional healthcare services to its clients.

ClearMedi Healthcare, a renowned healthcare company, is a joint venture between Medipass, a subsidiary of La Repubblica Group in Italy, KOS S.p.A. in Italy, and Clearview Healthcare India. Founded in 2010 by Shashi Kant Balyan, ClearMedi Healthcare manages complex clinical services, including oncology, nuclear medicine, and radiology, and operates standalone super specialty hospitals with over 350 hospital beds across different locations. ClearMedi runs its facilities in eight states and

a union territory and has emerged as a trusted leader in the healthcare sector, particularly in providing cancer care services.

Morgan Stanley PE Asia's acquisition of a controlling stake in ClearMedi Healthcare, a Delhi-NCR headquartered chain of oncology hospitals and radiation therapy centres, valued at approximately \$35 million (Rs 285 crore), is a testament to the global financial giant's commitment to the Indian healthcare sector. The deal involved the purchase of a majority stake from Italy's KOS Group and fresh equity injection into the company.